Research and Development Expenses Breakdown: Corcept Therapeutics Incorporated vs Soleno Therapeutics, Inc.

Biotech R&D: Corcept vs. Soleno's Decade of Innovation

__timestampCorcept Therapeutics IncorporatedSoleno Therapeutics, Inc.
Wednesday, January 1, 2014183720002242216
Thursday, January 1, 2015154190004536244
Friday, January 1, 2016238440005184803
Sunday, January 1, 2017403760003068742
Monday, January 1, 2018752470007178000
Tuesday, January 1, 20198901700016267000
Wednesday, January 1, 202011476400023191000
Friday, January 1, 202111386400021453000
Saturday, January 1, 202213099100015265000
Sunday, January 1, 202318435300025189000
Loading chart...

Data in motion

A Decade of Innovation: R&D Spending in Biotech

In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Corcept Therapeutics Incorporated and Soleno Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments.

Corcept Therapeutics: A Steady Climb

Corcept Therapeutics has shown a remarkable increase in R&D expenses, growing by over 900% from 2014 to 2023. This upward trajectory underscores their dedication to advancing medical therapies, particularly in the field of endocrinology.

Soleno Therapeutics: Consistent Yet Conservative

In contrast, Soleno Therapeutics has maintained a more conservative approach, with R&D expenses increasing by approximately 1,000% over the same period. Their focus remains on developing treatments for rare diseases, reflecting a strategic allocation of resources.

This data highlights the diverse approaches within the biotech sector, where innovation is driven by both aggressive and measured investment strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025